News

  • 09/01/10
    Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain
    <<click here for release>>

  • 08/25/10
    Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes
    <<click here for release>>

  • 1/26/10
    Afferent Pharmaceuticals Names Bruce G. McCarthy, M.D., as CEO
    <<click here for release>>

  • 12/16/09
    Roche Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing
    <<click here for release>>

Contact

Contact Afferent

Afferent Pharmaceuticals, Inc.
2755 Campus Drive, Suite 100
San Mateo, CA 94403
Phone: 650-286-1276
Fax: 650-286-1833

Information:
Email: info@afferentpharma.com

Media Contact:
Burns McClellan, Inc.
Justin Jackson
jjackson@burnsmc.com
Phone: 212-213-0006

Michelle Szwarcberg
mszwarcberg@burnsmc.com
Phone: 212-213-0006